Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669784 · ClinicalTrials.gov registry record · NA
Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
A NA study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT02669784 is a NA study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 34 participants.
The verdict
NCT02669784, a NA study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality. The hypothesis is that there is no difference in image quality using ultra-low dose contrast in CTA exams compared to routine, standard of care dose exams.
Interventions
- DRUG Low Dose Contrast (Omnipaque) 40mL
- DRUG Low Dose Contrast (Omnipaque) 50 mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669784
The ClinicalTrials.gov registry entry for NCT02669784 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low Dose Contrast (Omnipaque) 40mL is the first listed.
NCT02669784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669784 about?
NCT02669784 is a clinical study titled "Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study". The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality. The hypothesis is that there is no difference in image quality using ultra-low dose contrast in CTA exams compared...
What is the current status of trial NCT02669784?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2016-02. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02669784?
The interventions under investigation include: Low Dose Contrast (Omnipaque) 40mL (DRUG), Low Dose Contrast (Omnipaque) 50 mL (DRUG).
Who is sponsoring clinical trial NCT02669784?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.